# Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Source: https://onco.cc/trials/nct04906993/  
OnCo record `nct04906993` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Camrelizumab in cervical cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.

## Summary

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT04906993 by Jiangsu HengRui Medicine Co., Ltd., with 443 participants enrolled, started 2021-07-23 and due to reach its primary completion in 2025-06-10. Interventions recorded: camrelizumab； famitinib malate and platinum-based chemotherapy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04906993
- Phase: 3
- Setting: A Randomized, Open-Label, Controlled, Multi-Center Phase III Clinical Study of Camrelizumab Combined With Famitinib Malate Versus Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 443

## Sources

- ClinicalTrials.gov NCT04906993: https://clinicaltrials.gov/study/NCT04906993

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct04906993.json